<?xml version='1.0' encoding='utf-8'?>
<document id="25641606"><sentence text="Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin."><entity charOffset="36-48" id="DDI-PubMed.25641606.s1.e0" text="vortioxetine" /><entity charOffset="97-104" id="DDI-PubMed.25641606.s1.e1" text="aspirin" /><entity charOffset="109-117" id="DDI-PubMed.25641606.s1.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25641606.s1.e0" e2="DDI-PubMed.25641606.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25641606.s1.e0" e2="DDI-PubMed.25641606.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s1.e0" e2="DDI-PubMed.25641606.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25641606.s1.e1" e2="DDI-PubMed.25641606.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s1.e1" e2="DDI-PubMed.25641606.s1.e2" /></sentence><sentence text="Vortioxetine is an antidepressant with multimodal activity approved for the treatment of major depressive disorder"><entity charOffset="0-12" id="DDI-PubMed.25641606.s2.e0" text="Vortioxetine" /></sentence><sentence text=" Two separate randomized, placebo-controlled trials evaluated the effects of multiple doses of vortioxetine (10 mg/day) on the pharmacokinetics and pharmacodynamics of aspirin and warfarin in healthy volunteers"><entity charOffset="95-107" id="DDI-PubMed.25641606.s3.e0" text="vortioxetine" /><entity charOffset="168-175" id="DDI-PubMed.25641606.s3.e1" text="aspirin" /><entity charOffset="180-188" id="DDI-PubMed.25641606.s3.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25641606.s3.e0" e2="DDI-PubMed.25641606.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25641606.s3.e0" e2="DDI-PubMed.25641606.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s3.e0" e2="DDI-PubMed.25641606.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25641606.s3.e1" e2="DDI-PubMed.25641606.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s3.e1" e2="DDI-PubMed.25641606.s3.e2" /></sentence><sentence text=" In the aspirin study, subjects received vortioxetine 10 mg or placebo once daily for 14 days, followed by coadministration with aspirin 150 mg once daily for 6 days, in 2 periods with a crossover design"><entity charOffset="8-15" id="DDI-PubMed.25641606.s4.e0" text="aspirin" /><entity charOffset="41-53" id="DDI-PubMed.25641606.s4.e1" text="vortioxetine" /><entity charOffset="129-136" id="DDI-PubMed.25641606.s4.e2" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.25641606.s4.e0" e2="DDI-PubMed.25641606.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25641606.s4.e0" e2="DDI-PubMed.25641606.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s4.e0" e2="DDI-PubMed.25641606.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25641606.s4.e1" e2="DDI-PubMed.25641606.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s4.e1" e2="DDI-PubMed.25641606.s4.e2" /></sentence><sentence text=" In the warfarin study, subjects were randomized after reaching target international normalized ratio (INR) values on warfarin to receive vortioxetine 10 mg or matching placebo once daily for 14 days, with all subjects receiving a maintenance dose of warfarin (1-10 mg)"><entity charOffset="138-150" id="DDI-PubMed.25641606.s5.e0" text="vortioxetine" /><entity charOffset="251-259" id="DDI-PubMed.25641606.s5.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25641606.s5.e0" e2="DDI-PubMed.25641606.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25641606.s5.e0" e2="DDI-PubMed.25641606.s5.e1" /></sentence><sentence text=" Vortioxetine had no effect on the steady-state pharmacokinetic parameters of aspirin or its metabolite salicylic acid, and no statistically significant effect on the inhibition of arachidonic acid-, adenosine-5'-diphosphate-, or collagen-induced platelet aggregation at any time points"><entity charOffset="1-13" id="DDI-PubMed.25641606.s6.e0" text="Vortioxetine" /><entity charOffset="78-85" id="DDI-PubMed.25641606.s6.e1" text="aspirin" /><entity charOffset="104-118" id="DDI-PubMed.25641606.s6.e2" text="salicylic acid" /><entity charOffset="181-198" id="DDI-PubMed.25641606.s6.e3" text="arachidonic acid-" /><entity charOffset="200-225" id="DDI-PubMed.25641606.s6.e4" text="adenosine-5'-diphosphate-" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e0" e2="DDI-PubMed.25641606.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e0" e2="DDI-PubMed.25641606.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e0" e2="DDI-PubMed.25641606.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e0" e2="DDI-PubMed.25641606.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e0" e2="DDI-PubMed.25641606.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e1" e2="DDI-PubMed.25641606.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e1" e2="DDI-PubMed.25641606.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e1" e2="DDI-PubMed.25641606.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e1" e2="DDI-PubMed.25641606.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e2" e2="DDI-PubMed.25641606.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e2" e2="DDI-PubMed.25641606.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e2" e2="DDI-PubMed.25641606.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e3" e2="DDI-PubMed.25641606.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25641606.s6.e3" e2="DDI-PubMed.25641606.s6.e4" /></sentence><sentence text=" Coadministration of vortioxetine did not alter the pharmacokinetics of (R)- and (S)-warfarin enantiomers, or the mean coagulation parameters of warfarin treatment alone"><entity charOffset="21-33" id="DDI-PubMed.25641606.s7.e0" text="vortioxetine" /></sentence><sentence text=" Coadministration of vortioxetine doses in healthy volunteers had no effect on aspirin or warfarin pharmacokinetics or pharmacodynamics"><entity charOffset="21-33" id="DDI-PubMed.25641606.s8.e0" text="vortioxetine" /><entity charOffset="79-86" id="DDI-PubMed.25641606.s8.e1" text="aspirin" /><entity charOffset="90-98" id="DDI-PubMed.25641606.s8.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25641606.s8.e0" e2="DDI-PubMed.25641606.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25641606.s8.e0" e2="DDI-PubMed.25641606.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s8.e0" e2="DDI-PubMed.25641606.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25641606.s8.e1" e2="DDI-PubMed.25641606.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s8.e1" e2="DDI-PubMed.25641606.s8.e2" /></sentence><sentence text=" Vortioxetine was well tolerated when coadministered with aspirin or warfarin"><entity charOffset="1-13" id="DDI-PubMed.25641606.s9.e0" text="Vortioxetine" /><entity charOffset="58-65" id="DDI-PubMed.25641606.s9.e1" text="aspirin" /><entity charOffset="69-77" id="DDI-PubMed.25641606.s9.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25641606.s9.e0" e2="DDI-PubMed.25641606.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25641606.s9.e0" e2="DDI-PubMed.25641606.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s9.e0" e2="DDI-PubMed.25641606.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25641606.s9.e1" e2="DDI-PubMed.25641606.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25641606.s9.e1" e2="DDI-PubMed.25641606.s9.e2" /></sentence><sentence text=" " /></document>